Nonobstructive Hypertrophic Cardiomyopathy

Aficamten’s Impact on Cardiac Function and Structure in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM Trial

Aficamten significantly improves diastolic function and cardiac structure in symptomatic nonobstructive hypertrophic cardiomyopathy, indicating benefits beyond outflow tract gradient reduction.